Drug Profile
Certolizumab pegol biosimilar - Xbrane
Alternative Names: BIIB-801; XcimzaneLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Xbrane
- Class Anti-inflammatories; Antirheumatics; Fab fragments; Monoclonal antibodies; Polyethylene glycols
- Mechanism of Action Immunosuppressants; Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Psoriasis
- No development reported Ankylosing spondylitis; Crohn's disease; Psoriatic arthritis; Rheumatoid arthritis; Spondylitis
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for preclinical development in Crohn's-disease in Sweden (SC)
- 28 Feb 2024 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Sweden (SC)
- 23 Feb 2022 Xbrane Biopharma plans phase I and phase III trials in Autoimmune disorders